期刊文献+

前蛋白转化酶枯草溶菌素9与动脉粥样硬化 被引量:4

Proprotein Convertase Subtilisin/Kexin Type 9 and Atherosclerosis
下载PDF
导出
摘要 动脉粥样硬化是严重危害人类健康的重大疾病。新近的研究表明,前蛋白转化酶枯草溶菌素9作为降解低密度脂蛋白受体的重要分子,影响前蛋白转化酶枯草溶菌素9-低密度脂蛋白受体途径导致低密度脂蛋白代谢异常,与动脉粥样硬化形成的关系密切。现就前蛋白转化酶枯草溶菌素9影响动脉粥样硬化研究进展做一综述。 Atherosclerosis is a serious disease that is harmful to human health. Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ), a newly recognized protein, which plays a key role in cholesterol homeostasis by enhancing the degradation of hepatic low-density lipoprotein receptor and causing marked increases in low-density lipoprotein cholesterol concentration and atherosclerosis. This review pro- vides important links between PCSK9, low-density lipoprotein receptor and the mechanisms of atherosclerosis.
作者 胥雪莲 何川
出处 《心血管病学进展》 CAS 2016年第1期50-53,共4页 Advances in Cardiovascular Diseases
基金 重庆市科委自然科学基金计划资助项目(cstc2012jj A10045) 重庆市渝中区科委科技计划项目(20130129)
关键词 前蛋白转化酶枯草溶菌素9 动脉粥样硬化 低密度脂蛋白受体 Proprotein convertase subtilisin/kexin type 9 Atherosclerosis Low-density lipoprotein receptor
  • 相关文献

参考文献34

  • 1Benjannet S, Rhainds D, Essalmani R, et al. NARC-IIPCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein(LDL) receptor and LDL cholesterol[J]. J bioi Chem,2004,279(47) :4886548875. 被引量:1
  • 2Seidah NG, Awan Z, Chretien M, et al. PCSK9: a key modulator of cardiovascular health[J], Cire Res, 2014,114(6) :1022-1036. 被引量:1
  • 3Zaid A, Roubtsova A, Essalmani R, etal. Proprotein convertase subtilisinl kexin type 9 ( PCSK9) : hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration [J]. Hepatology, 2008 ,48 (2) :646-654. 被引量:1
  • 4Dong B, Wu M, Li H, et al. Strong induction of PCSK9 gene expression through HNFI alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters [J]. J Lipid Res, 20 10 , 51(6) :1486-1495. 被引量:1
  • 5Li H, Dong B, Park SW, et al. Hepatocyte nuclear factor I alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine[J]. J bioi Chem,2009,284(42) :28885-28895. 被引量:1
  • 6Berger JM, Vaillant N, le May C, et al. PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension [J]. Atherosclerosis,2015,239(1) :252-259. 被引量:1
  • 710 Surdo P, Bottomley MJ, Calzetta A, et al. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH [J]. EMBO Rep, 2011,12( 12) :1300-1305. 被引量:1
  • 8Tveten K, Holla 0L, Cameron J, et al. Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification[J]. Hum Mol Genet,2012,21(6) :1402-1409. 被引量:1
  • 9Poirier S, Mayer G, Poupon V, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route[J]. J bioi Chern ,2009 ,284(42) :28856-28864. 被引量:1
  • 10J Lagace TA, Curtis DE, Gamti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice[J], J Clin Invest ,2006 , 116( 11) :2995-3005. 被引量:1

同被引文献25

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部